Moxonidine treatment was associated with lower recurrence risk after adjustment for age , body mass index , number of AF episodes in the previous year , and left atrial diameter ( adjusted hazard ratio , 0.35 [ 95 % CI , 0.22-0 .55 ] ; P < 0.001 ) .